866-997-4948(US-Canada Toll Free)

Osteosarcoma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Oncology

No. of Pages : 90 Pages

Osteosarcoma Pipeline Review, H1 2014, provides an overview of the Osteosarcomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Osteosarcoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Osteosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Osteosarcoma Overview 8
Therapeutics Development 9
Pipeline Products for Osteosarcoma - Overview 9
Pipeline Products for Osteosarcoma - Comparative Analysis 10
Osteosarcoma - Therapeutics under Development by Companies 11
Osteosarcoma - Therapeutics under Investigation by Universities/Institutes 13
Osteosarcoma - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Osteosarcoma - Products under Development by Companies 17
Osteosarcoma - Products under Investigation by Universities/Institutes 18
Osteosarcoma - Companies Involved in Therapeutics Development 19
Shionogi & Co., Ltd. 19
GlaxoSmithKline plc 20
Oncolytics Biotech Inc. 21
Med Discovery SA 22
Aileron Therapeutics, Inc. 23
Merrimack Pharmaceuticals, Inc. 24
Bellicum Pharmaceuticals, Inc. 25
Sutro Biopharma, Inc. 26
Eleison Pharmaceuticals, Inc. 27
Apoplogic Pharmaceuticals, Inc. 28
Osteosarcoma - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
cisplatin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
pelareorep - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Angiotensin 1-7 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
sirolimus + [cyclophosphamide] - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
pazopanib hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
irinotecan sucrosofate liposomal - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
HU14.18K322A - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
PBF Peptide Vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Dendritic Cell Vaccine + [decitabine] + [imiquimod] - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Peptide Cocktail Vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Cell Therapy to Target GD2 Antigen for Solid Tumors - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MDRG-01 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ALRN-6924 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MBC-11 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
(HPMA + TNP-470 + alendronate) - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
LLL-12 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Fasaret - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Drugs Targeting Thymidylate Synthase And Dihydrofolate Reductase - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
De-Methylated Derivatives Of Colchicine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Bispecific Antibodies to Target GD2 for Osteosarcoma - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Osteosarcoma - Recent Pipeline Updates 72
Osteosarcoma - Dormant Projects 83
Osteosarcoma - Discontinued Products 84
Osteosarcoma - Product Development Milestones 85
Featured News & Press Releases 85
Mar 17, 2014: First Cancer Trial Launched Using CAR T Cells Engineered with a Safety Switch 85
Oct 08, 2013: ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma 86
Jun 24, 2011: PCI Biotech Announces Main Results Of Full Phase I/II Study Of Amphinex 86
Apr 27, 2011: Oncolytics Biotech Announces Start Of Conformity Testing With SAFC 87
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014 87

Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 90
Disclaimer 90

List of Table


Number of Products under Development for Osteosarcoma, H1 2014 9
Number of Products under Development for Osteosarcoma - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Osteosarcoma - Pipeline by Shionogi & Co., Ltd., H1 2014 19
Osteosarcoma - Pipeline by GlaxoSmithKline plc, H1 2014 20
Osteosarcoma - Pipeline by Oncolytics Biotech Inc., H1 2014 21
Osteosarcoma - Pipeline by Med Discovery SA, H1 2014 22
Osteosarcoma - Pipeline by Aileron Therapeutics, Inc., H1 2014 23
Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 24
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014 25
Osteosarcoma - Pipeline by Sutro Biopharma, Inc., H1 2014 26
Osteosarcoma - Pipeline by Eleison Pharmaceuticals, Inc., H1 2014 27
Osteosarcoma - Pipeline by Apoplogic Pharmaceuticals, Inc., H1 2014 28
Assessment by Monotherapy Products, H1 2014 29
Assessment by Combination Products, H1 2014 30
Number of Products by Stage and Target, H1 2014 33
Number of Products by Stage and Mechanism of Action, H1 2014 36
Number of Products by Stage and Route of Administration, H1 2014 38
Number of Products by Stage and Molecule Type, H1 2014 40
Osteosarcoma Therapeutics - Recent Pipeline Updates, H1 2014 72
Osteosarcoma - Dormant Projects, H1 2014 83
Osteosarcoma - Discontinued Products, H1 2014 84

List of Chart


Number of Products under Development for Osteosarcoma, H1 2014 9
Number of Products under Development for Osteosarcoma - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 29
Assessment by Combination Products, H1 2014 30
Number of Products by Top 10 Target, H1 2014 31
Number of Products by Stage and Top 10 Target, H1 2014 32
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 37
Number of Products by Stage and Top 10 Route of Administration, H1 2014 38
Number of Products by Top 10 Molecule Type, H1 2014 39
Number of Products by Stage and Top 10 Molecule Type, H1 2014 40

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *